FFRangio Pooled Analysis from 5 Prospective Cohort Studies

FFRangio Pooled Analysis from 5 Prospective Cohort Studies

Excellent diagnostic performance: 91% sensitivity, 94% specificity, and 93% diagnostic accuracy

This lesion-level pooled data analysis of 588 patients and 700 lesions represents the “largest and most diverse cohort of any single angiogram-based FFR technology reported.” Results indicate FFRangio has excellent diagnostic performance, strong correlation, and that results were robust across a wide spectrum of patients and lesion characteristics.

FFRangio in Dual/Triple Vessel Disease

Excellent diagnostic performance, with sensitivity, specificity and accuracy all above 92%; FFRangio was 40% faster that wire-based FFR

This prospective clinical study conducted at Gifu Heart Centre, Japan—evaluated the diagnostic performance of FFRangio in 50 patients with dual or triple vessel CAD compared to wire-based FFR. Continue reading “FFRangio in Dual/Triple Vessel Disease”

FAST-FFR Pivotal Trial

92% Diagnostic Accuracy, 94% Sensitivity, and 91% Specificity

The FAST-FFR pivotal trial was a prospective multicenter, international trial designed to determine the accuracy of FFRangio in clinical practice compared to traditional wire-based FFR. The trial included 301 patients and 319 vessels at 10 clinical sites. The results demonstrated excellent diagnostic performance, including in the grey zone between FFR values of 0.75 and 0.85. Continue reading “FAST-FFR Pivotal Trial”

Learn how the CathWorks FFRangio® System can impact your practice.


    expand_lessBack to top of page

    We use cookies to enhance your experience. By continuing to visit this site, you agree to our use of cookies. Terms and Conditions